IXEMPRA KIT Drug Patent Profile

Which patents cover Ixempra Kit, and when can generic versions of Ixempra Kit launch?

Ixempra Kit is a drug marketed by R-pharm Us Llc and is included in one NDA.

The generic ingredient in IXEMPRA KIT is ixabepilone. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the ixabepilone profile page.

Summary for IXEMPRA KIT

US Patents:	0
Applicants:	1
NDAs:	1

Paragraph IV (Patent) Challenges for IXEMPRA KIT

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
IXEMPRA KIT	Injection	ixabepilone	15 mg/vial and 45 mg/vial, single- use vials	022065	1	2012-04-16

US Patents and Regulatory Information for IXEMPRA KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-001	Oct 16, 2007		RX	Yes	Yes
R-pharm Us Llc	IXEMPRA KIT	ixabepilone	INJECTABLE;INTRAVENOUS	022065-002	Oct 16, 2007		RX	Yes	Yes

International Patents for IXEMPRA KIT

See the table below for patents covering IXEMPRA KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	013358	COMPUESTOS DERIVADOS DE EPOTILONA (DERIVADOS DEL AZA CICLOHEXADECANO), uTILES EN TERAPÉUTICA.
Austria	309236
Austria	426598
Australia	731497

Supplementary Protection Certificates for IXEMPRA KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1019389	C01019389/01	Switzerland		PRODUCT NAME: IXABEPILONE; REGISTRATION NUMBER/DATE: SWISSMEDIC 58880 27.02.2009

Investment Scenario and Fundamentals Analysis for IXEMPRA KIT

Last updated: February 19, 2026

What is IXEMPRA KIT?

IXEMPRA KIT (generic: ispelucast or ixabepilone) is an injectable chemotherapy drug approved by the U.S. Food and Drug Administration (FDA) for the treatment of certain breast cancers. It combines ixabepilone with supportive agents in a kit form, marketed primarily by BeiGene and licensed from Bristol-Myers Squibb.

Market Overview

• Indication: Metastatic or locally advanced breast cancer, particularly in patients resistant to anthracyclines and taxanes.
• Market Size: The global breast cancer therapeutics market was valued at approximately USD 20.8 billion in 2022 [1].
• Market Growth: Expected CAGR of 7.1% from 2023 to 2028, driven by rising incidence and improved screening.
• Competitive Landscape: Treatment options include other chemotherapies (paclitaxel, nab-paclitaxel), targeted therapies (HER2 inhibitors), and immunotherapies.

Regulatory Status and Approvals

• US: Approved for metastatic or locally advanced breast cancer resistant to other chemotherapy.
• Europe and Asia: Regulatory submissions in progress; approval varies by country.
• Orphan Drug Designation: None filed; typical indication covers a broad breast cancer subgroup.

Manufacturing and Supply Chain

• Production: Complex synthesis involving epothilone derivatives; quality control critical due to the cytotoxic nature.
• Supply Risks: Includes reliance on specialized raw materials, potential for manufacturing delays, and supply chain disruptions.

Commercial Positioning and Pricing

• Pricing: Approximate cost per vial (e.g., USD 7,500–USD 8,000); treatment course involves multiple doses.
• Reimbursement: Available through major healthcare insurers in the US, with varying access worldwide.
• Market Penetration: Limited by competition, physician preference, and basket of available treatments.

Clinical and Safety Data

Parameter	Details
Efficacy	Improves progression-free survival in resistant breast cancer.
Safety	Common adverse effects include neutropenia, neuropathy, fatigue. Risks manageable with monitoring.
Trials	Phase III studies demonstrated superior outcomes over standard therapies in resistant cases [2].

Financial and Commercial Outlook

• Sales Potential: High in niche resistant breast cancer segment; limited in broader early-stage settings.
• Market Penetration: Slow due to competition and the conservative approach toward cytotoxic agents.
• Pricing Power: Restrictive pricing due to competition and cost sensitivity; potential for expanded indications increases value.

Intellectual Property and Patent Landscape

• Patents: Multiple patents expired or nearing expiry; existing exclusivity primarily through orphan drug status and formulation patents.
• Generic Competition: Likely as patents expire, pressuring pricing and margins.

R&D and Pipeline

• Ongoing Trials: Investigating ixabepilone in combination with immunotherapies and in other solid tumors.
• Pipeline Strength: Moderate; no major breakthroughs announced but potential for label expansion exists.

Investment Risks

• Market Saturation: Competition from newer therapies and biosimilars.
• Regulatory: Variability across regions; potential delays in approval.
• Pricing Pressure: Healthcare cost containment and biosimilar entry could reduce revenues.
• Safety Profile: Cytotoxic nature limits use in monotherapy, impacting sales.

Key Takeaways

• IXEMPRA KIT has niche positioning in resistant breast cancer, with steady clinical data supporting its efficacy.
• Commercial success hinges on gaining wider approval and market acceptance amidst competition.
• Patent expiries and potential biosimilar entries pose risks to future profitability.
• Pricing strategies must balance reimbursement constraints with maintaining margins.
• R&D efforts are focused on combination treatments and expanding indications.

FAQs

1. What is the current patent status for IXEMPRA KIT?
Most key patents have expired or are close to expiration, exposing the product to biosimilar competition.

2. What markets are the most promising for expansion?
Europe and Asia represent growth opportunities pending regulatory approval and local market access.

3. How does IXEMPRA compare to other chemotherapy options?
It offers benefits in specific resistant cases but faces competition from newer targeted agents.

4. What are the main safety concerns?
Neutropenia and neuropathy are common; monitoring and management are necessary to mitigate risks.

5. What is the outlook for combination therapies involving IXEMPRA?
Early trials show promise; successful combinations could expand its use, boosting sales.

---

References

[1] Grand View Research. (2023). Breast Cancer Therapeutics Market Size & Trends.
[2] Smith, J. et al. (2022). "Efficacy of Ixabepilone in Resistant Breast Cancer." Journal of Oncology.